Implementing Minor Changes is Hard to Do Under Variations Regulation
This article was originally published in The Gold Sheet
Executive Summary
European generic drug makers say that it is difficult to implement Type IA changes under the variations regulation because of all the paperwork involved in submitting these changes to competent authorities. A 26 percent fee hike in filing variations is also making it more costly and difficult for manufacturers to justify making changes.
You may also be interested in...
Minor Changes Still Burdensome to Report Under Revised Variations Regulation, European Industry and Competent Authorities Complain
Latest EU variations rewrite leaves both industry and regulators with concerns. Minor changes would still be difficult to implement and pre-notification requirements are seen as unworkable. A plan to subject all biologics changes to prior approval draws ire of biotech sector
US FDA Mulls Pilot To Examine Separate Review Pathway For Novel Excipients
Proposal could yield a bounty of new options for innovative drug delivery systems.
US FDA Says Data Integrity Remains Challenging For API Manufacturers
Data integrity issues were raised in many warning letters to active pharmaceutical ingredient manufacturers over the past four years.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports